Coherus Oncology (CHRS)
Commercializes LOQTORZI while advancing mid-stage immuno-oncology antibodies.
$1.31
After-hours close+0.01 (+0.77%)
At close$1.30(−5.11%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 44 days
EPS estimate
−$0.21
Revenue estimate
$16.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.44−$0.35−$0.34−$0.33−$0.34−$0.25−$0.19Pending
Estimate−$0.10−$0.31−$0.31−$0.32−$0.36−$0.26−$0.25−$0.21
Surprise−340.0%−12.9%−9.7%−3.1%+4.2%+5.1%+24.0%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$54.1M$7.6M$10.3M$11.6M$12.7M$12.3M$14.3MPending
Estimate$44.1M$61.0M$12.0M$14.1M$13.9M$14.2M$14.4M$16.0M
Surprise+22.6%−87.5%−14.5%−17.9%−8.4%−13.4%−0.7%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.00 | — | — |
| Sep 2028 | $0.00 | — | — |
| Jun 2028 | $0.00 | — | — |
| Mar 2028 | $0.00 | — | — |
| Dec 2027 | −$0.19 | — | — |
| Sep 2027 | −$0.20 | — | — |
| Jun 2027 | −$0.21 | — | — |
| Mar 2027 | −$0.17 | — | — |
| Dec 2026 | −$0.22 | — | — |
| Nov 2026 | −$0.21 | — | — |
| Aug 2026 | −$0.25 | −$0.19 | +24.0% |
| May 2026 | −$0.26 | −$0.25 | +5.1% |
| Mar 2026 | −$0.36 | −$0.34 | +4.2% |
| Nov 2025 | −$0.32 | −$0.33 | −3.1% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.00 | — | — | $49.0M | — | — | — |
| Sep 2028 | $0.00 | — | — | $47.2M | — | — | — |
| Jun 2028 | $0.00 | — | — | $43.6M | — | — | — |
| Mar 2028 | $0.00 | — | — | $41.8M | — | — | — |
| Dec 2027 | −$0.19 | — | — | $33.7M | — | — | — |
| Sep 2027 | −$0.20 | — | — | $29.4M | — | — | — |
| Jun 2027 | −$0.21 | — | — | $23.9M | — | — | — |
| Mar 2027 | −$0.17 | — | — | $22.4M | — | — | — |
| Dec 2026 | −$0.22 | — | — | $18.2M | — | — | — |
| Nov 5, 2026 | −$0.21 | — | — | $16.0M | — | — | — |
| Aug 5, 2026 | −$0.25 | −$0.19 | +24.0% | $14.4M | $14.3M | −0.7% | −13.1% |
| May 11, 2026 | −$0.26 | −$0.25 | +5.1% | $14.2M | $12.3M | −13.4% | −12.3% |
| Mar 9, 2026 | −$0.36 | −$0.34 | +4.2% | $13.9M | $12.7M | −8.4% | +1.0% |
| Nov 6, 2025 | −$0.32 | −$0.33 | −3.1% | $14.1M | $11.6M | −17.9% | −10.1% |
| Aug 7, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 10, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 13, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 2, 2023 | |||||||
| May 8, 2023 | |||||||
| Mar 6, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 17, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 24, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 27, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 8, 2018 | |||||||
| Nov 6, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 13, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 |